CLVS
Bueno, pues el pipeline de esta también me gusta mucho....
Son 4 fases III, una de las cuales es la que han publicado resultados hoy.....
Se trata de una empresa oncológica 100%....
Por lo que he leído, en la PR de hoy, no está la totalidad de los datos del ensayo, que se darán en la conferencia prevista a las 14:35 PM CT, o sea, al cierre de mercado...
https://clovisoncology.com/pipeline/pipeline-overview/Previsiones de catalizadores para 2021...
"Anticipated Rubraca Pipeline Events in 2021
Top-line data from the ATHENA Phase 3 study in first-line maintenance treatment ovarian cancer setting evaluating Rubraca monotherapy versus placebo are expected in the second-half of 2021, contingent on achieving sufficient PFS events. Data from the combination arm of Rubraca plus Opdivo versus Rubraca monotherapy are expected a year or more later.
LODESTAR, the Company’s Phase 2 trial of Rubraca in patients with solid tumors with deleterious mutations in homologous recombination repair (HRR) genes is currently enrolling. This study may be registration-enabling with a potential regulatory filing by the end of 2021 or first-half 2022.
LuMIERE Phase 1/2 Study of FAP-2286 Expected to Begin 1H 2021
FAP-2286 is Clovis Oncology’s peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP) and represents its lead candidate in the PTRT development program. Clovis intends to initiate the Phase 1/2 LuMIERE clinical study of lutetium-177 labeled FAP-2286 (177Lu-FAP-2286) to determine the dose and tolerability of the FAP-targeting therapeutic agent (Phase 1), with expansion cohorts planned in multiple tumor types (Phase 2). FAP-2286 labelled with gallium-68 (68Ga-FAP-2286) will be utilized as a diagnostic to identify patients with FAP-positive tumors appropriate for treatment with the therapeutic agent. The LuMIERE study is expected to begin in the first half of 2021, pending acceptance by the FDA of gallium-68 CMC data from clinical sites.Other studies of FAP-2286 linked to an alpha-particle emitting radionuclide and combination studies are also being planned.
Interim LIO-1 data of Lucitanib and Opdivo in Combination Expected in 2021
The Phase 2 part of the LIO-1 study of lucitanib in combination with Opdivo continues to enroll patients with gynecologic cancers, and Clovis Oncology intends to present initial data at 2021 medical meetings, which are expected to include interim results from the ovarian and endometrial cancer expansion cohorts."
Un saludo y muchos aciertos...
